For-profit hospitals cost the Medicare program more than not-for-profit hospitals, according to a recent article published in the New England Journal of Medicine (vol. 341, no. 6).
For-profit hospitals cost the Medicare program more than not-for-profit hospitals, according to a recent article published in the New England Journal of Medicine (vol. 341, no. 6).
Co-authors Elaine M. Silverman, Jonathon S. Skinner and Elliot S. Fisher used American Hospital Association data to calculate the 1989, 1992 and 1995 spending rates in for-profit and non-profit hospital areas.
"The major findings in the study were that Medicare spending in areas served by for-profit hospitals was higher than in areas served by non-profit hospitals." said Elaine Silverman, co-author of the article.
Though the report doesn't give a reason for the spending differences, Silverman ventured several guesses. "There are differences in patient populations that correspond to a need for greater services in the for-profit areas. However, we don't think that's a likely explanation because we controlled for many characteristics of the hospital service areas and the patients who lived in them that might influence cost. We think that the difference is likely due to differences in the organizational behavior of these hospitals that might influence cost."
Not everyone agreed with the results of the report, however. Both the Federation of American Health Systems and the American Hospital Association accused the authors of the study of flawed reasoning and editorial bias.
"The statistical merit of this piece is highly suspect," said Tom Scully, president and CEO of the Federation. "This four-page study asks readers to blindly accept much of the methodology, which we need to know more about. Such as: How does the study account for the hospital wage index, which can account for as much as a 100% variation in hospital payments among areas for the same service?"
Mary Grealy, chief Washington council for the AHA, also accused the authors of failing to take all the necessary factors into consideration before coming to their conclusions. She said, "There are certain adjustments for disproportionate share hospitals, for teaching hospitals, there are all these different adjustments that hospitals get that do result in higher Medicare spending that [the authors] do not seem to have accounted for in their report." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.